NCT05294978 EyeConic: Qualification for Cone-Optogenetics
| NCT ID | NCT05294978 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute of Molecular and Clinical Ophthalmology Basel |
| Condition | Retinal Dystrophies |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2021-07-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2021-07-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.
Eligibility Criteria
Inclusion Criteria (patients): * Diagnosis of generalized IRD * Low vision as defined as visual acuity worse or equal to 0.05 (or 20/400) in the study eye * Availability of macular optical coherence tomography (OCT) Inclusion Criteria (controls): * Normal ophthalmic findings * Availability of macular optical coherence tomography (OCT) Exclusion Criteria (all): * Other eye diseases with a significant effect on vision or retinal structure * Extraocular disease affecting retinal structure such as neurodegenerative diseases
Contact & Investigator
Nicolas Feltgen, MD
PRINCIPAL INVESTIGATOR
University Hospital Basel/Institute of Molecular and Clinical Ophthalmology Basel, Switzerland
Frequently Asked Questions
Who can join the NCT05294978 clinical trial?
This trial is open to participants of all sexes, studying Retinal Dystrophies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05294978 currently recruiting?
Yes, NCT05294978 is actively recruiting participants. Contact the research team at lucas.janeschitz@iob.ch for enrollment information.
Where is the NCT05294978 trial being conducted?
This trial is being conducted at San Francisco, United States, Miami, United States, Pittsburgh, United States, Beijing, China and 5 additional locations.
Who is sponsoring the NCT05294978 clinical trial?
NCT05294978 is sponsored by Institute of Molecular and Clinical Ophthalmology Basel. The principal investigator is Nicolas Feltgen, MD at University Hospital Basel/Institute of Molecular and Clinical Ophthalmology Basel, Switzerland. The trial plans to enroll 1,000 participants.